Novo Nordisk Faces Generic Onslaught and Dividend Adjustment in Key Market

Novo Nordisk's semaglutide patent expires in India, sparking generic price war. Stock hits 52-week low while trading ex-dividend, amid AI-driven competition from rivals.

Investors in Novo Nordisk are navigating a dual challenge this week. The Danish pharmaceutical giant's blockbuster drug, semaglutid, has lost its patent protection in India, unleashing a wave of low-cost generic competitors. This structural shift coincides with the stock trading ex-dividend, adding another layer of complexity for shareholders.

A Strategic Pivot Amid Price Erosion

The Indian market for weight-loss medications is undergoing a dramatic transformation. As of March 20, approximately 40 domestic drugmakers, including industry leaders Sun Pharma, Dr. Reddy’s, and Zydus, have launched their own versions of semaglutid. This intense competition has led to a precipitous drop in costs for patients. The price of a monthly injection pen has collapsed from a previous high of 26,000 rupees to a new range of just 3,500 to 4,500 rupees.

While this price erosion pressures Novo Nordisk's profit margins, it also unlocks a massive potential market in a country with an estimated 250 million obese individuals. Industry forecasts suggest the regional market for semaglutid could expand from $26 million in 2024 to $347 million by 2035. To capture long-term value from this expected growth in GLP-1 agonist demand, the company must now adapt its strategy for emerging economies. Key hurdles include managing the complex cold-chain logistics for its biological products and adjusting the sophisticated production of its pre-filled pens to compete with the significantly lower price points set by generic manufacturers.

Competitive Landscape Intensifies with AI Focus

The pressure on Novo Nordisk is not confined to pricing in Asia. Global rivals are making substantial investments to bolster their future drug pipelines. In a notable move highlighting an industry trend, competitor Eli Lilly recently entered a licensing agreement with biotechnology firm Insilico Medicine. The deal, with a potential total value of up to $2.75 billion, grants Lilly exclusive worldwide rights to AI-discovered drug candidates targeting diabetes. This underscores a broader shift toward leveraging artificial intelligence and external partnerships in the development of next-generation therapies.

Share Price Weakness Meets Dividend Date

Beyond these strategic headwinds, immediate shareholder attention is on the dividend. The stock began trading ex-dividend on Monday, a technical factor that typically exerts downward pressure on the share price. This comes at a time when the equity is already under significant strain. On Friday, the shares touched a new 52-week low of €30.48, marking a decline of nearly 32% since the start of the year. The actual dividend payment of $1.2751 per share is scheduled for distribution on April 8.

The confluence of generic competition in a high-growth market and near-term technical factors presents a critical juncture for Novo Nordisk as it seeks to defend its leadership in the obesity and diabetes treatment sector.